Literature DB >> 25097189

Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1-D3 receptor heterotetramer.

Xavier Guitart1, Gemma Navarro1, Estefania Moreno1, Hideaki Yano1, Ning-Sheng Cai1, Marta Sánchez-Soto1, Sandeep Kumar-Barodia1, Yamini T Naidu1, Josefa Mallol1, Antoni Cortés1, Carme Lluís1, Enric I Canela1, Vicent Casadó1, Peter J McCormick1, Sergi Ferré2.   

Abstract

The dopamine D1 receptor-D3 receptor (D1R-D3R) heteromer is being considered as a potential therapeutic target for neuropsychiatric disorders. Previous studies suggested that this heteromer could be involved in the ability of D3R agonists to potentiate locomotor activation induced by D1R agonists. It has also been postulated that its overexpression plays a role in L-dopa-induced dyskinesia and in drug addiction. However, little is known about its biochemical properties. By combining bioluminescence resonance energy transfer, bimolecular complementation techniques, and cell-signaling experiments in transfected cells, evidence was obtained for a tetrameric stoichiometry of the D1R-D3R heteromer, constituted by two interacting D1R and D3R homodimers coupled to Gs and Gi proteins, respectively. Coactivation of both receptors led to the canonical negative interaction at the level of adenylyl cyclase signaling, to a strong recruitment of β-arrestin-1, and to a positive cross talk of D1R and D3R agonists at the level of mitogen-activated protein kinase (MAPK) signaling. Furthermore, D1R or D3R antagonists counteracted β-arrestin-1 recruitment and MAPK activation induced by D3R and D1R agonists, respectively (cross-antagonism). Positive cross talk and cross-antagonism at the MAPK level were counteracted by specific synthetic peptides with amino acid sequences corresponding to D1R transmembrane (TM) domains TM5 and TM6, which also selectively modified the quaternary structure of the D1R-D3R heteromer, as demonstrated by complementation of hemiproteins of yellow fluorescence protein fused to D1R and D3R. These results demonstrate functional selectivity of allosteric modulations within the D1R-D3R heteromer, which can be involved with the reported behavioral synergism of D1R and D3R agonists. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25097189      PMCID: PMC4164978          DOI: 10.1124/mol.114.093096

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  30 in total

1.  Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.

Authors:  Ko-Woon Lee; Jang-Hee Hong; In Young Choi; Yongzhe Che; Ja-Kyeong Lee; Sung-Don Yang; Chang-Woo Song; Ho Sung Kang; Jae-Heun Lee; Jai Sung Noh; Hee-Sup Shin; Pyung-Lim Han
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 2.  Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index.

Authors:  Vincent Casadó; Antoni Cortés; Francisco Ciruela; Josefa Mallol; Sergi Ferré; Carmen Lluis; Enric I Canela; Rafael Franco
Journal:  Pharmacol Ther       Date:  2007-06-14       Impact factor: 12.310

3.  Detection of heteromerization of more than two proteins by sequential BRET-FRET.

Authors:  Paulina Carriba; Gemma Navarro; Francisco Ciruela; Sergi Ferré; Vicent Casadó; Luigi Agnati; Antoni Cortés; Josefa Mallol; Kjell Fuxe; Enric I Canela; Carmen Lluís; Rafael Franco
Journal:  Nat Methods       Date:  2008-06-29       Impact factor: 28.547

4.  A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation.

Authors:  T E Hebert; S Moffett; J P Morello; T P Loisel; D G Bichet; C Barret; M Bouvier
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

5.  Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor.

Authors:  S W Robinson; M G Caron
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

6.  Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities.

Authors:  J K Staley; D C Mash
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

7.  Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein.

Authors:  Jean-Louis Banères; Joseph Parello
Journal:  J Mol Biol       Date:  2003-06-13       Impact factor: 5.469

8.  Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization.

Authors:  Chiara Fiorentini; Chiara Busi; Emanuela Gorruso; Cecilia Gotti; Pierfranco Spano; Cristina Missale
Journal:  Mol Pharmacol       Date:  2008-04-18       Impact factor: 4.436

9.  Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects.

Authors:  Estefanía Moreno; David Moreno-Delgado; Gemma Navarro; Hanne M Hoffmann; Silvia Fuentes; Santi Rosell-Vilar; Paola Gasperini; Mar Rodríguez-Ruiz; Mireia Medrano; Josefa Mallol; Antoni Cortés; Vicent Casadó; Carme Lluís; Sergi Ferré; Jordi Ortiz; Enric Canela; Peter J McCormick
Journal:  J Neurosci       Date:  2014-03-05       Impact factor: 6.167

Review 10.  Visualization of molecular interactions by fluorescence complementation.

Authors:  Tom K Kerppola
Journal:  Nat Rev Mol Cell Biol       Date:  2006-06       Impact factor: 94.444

View more
  50 in total

1.  Antipsychotic-Like Efficacy of Dopamine D2 Receptor-Biased Ligands is Dependent on Adenosine A2A Receptor Expression.

Authors:  Kristoffer Sahlholm; Maricel Gómez-Soler; Marta Valle-León; Marc López-Cano; Jaume J Taura; Francisco Ciruela; Víctor Fernández-Dueñas
Journal:  Mol Neurobiol       Date:  2017-08-05       Impact factor: 5.590

Review 2.  Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.

Authors:  Sergi Ferré
Journal:  Psychopharmacology (Berl)       Date:  2016-01-20       Impact factor: 4.530

3.  D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.

Authors:  David Lindenbach; Banibrata Das; Melissa M Conti; Samantha M Meadows; Aloke K Dutta; Christopher Bishop
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

4.  Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.

Authors:  Oscar Solís; Jose Ruben Garcia-Montes; Aldo González-Granillo; Ming Xu; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2017-01-01       Impact factor: 5.357

5.  Adenosine A1-Dopamine D1 Receptor Heteromers Control the Excitability of the Spinal Motoneuron.

Authors:  Marla Rivera-Oliver; Estefanía Moreno; Yocasta Álvarez-Bagnarol; Christian Ayala-Santiago; Nicole Cruz-Reyes; Gian Carlo Molina-Castro; Stefan Clemens; Enric I Canela; Sergi Ferré; Vicent Casadó; Manuel Díaz-Ríos
Journal:  Mol Neurobiol       Date:  2018-05-24       Impact factor: 5.590

6.  Functional μ-Opioid-Galanin Receptor Heteromers in the Ventral Tegmental Area.

Authors:  Estefanía Moreno; César Quiroz; William Rea; Ning-Sheng Cai; Josefa Mallol; Antoni Cortés; Carme Lluís; Enric I Canela; Vicent Casadó; Sergi Ferré
Journal:  J Neurosci       Date:  2016-12-22       Impact factor: 6.167

7.  Allosterism within δ Opioid-κ Opioid Receptor Heteromers in Peripheral Sensory Neurons: Regulation of κ Opioid Agonist Efficacy.

Authors:  Blaine A Jacobs; Miryam M Pando; Elaine Jennings; Teresa A Chavera; William P Clarke; Kelly A Berg
Journal:  Mol Pharmacol       Date:  2018-02-07       Impact factor: 4.436

8.  Orexin-corticotropin-releasing factor receptor heteromers in the ventral tegmental area as targets for cocaine.

Authors:  Gemma Navarro; César Quiroz; David Moreno-Delgado; Adam Sierakowiak; Kimberly McDowell; Estefanía Moreno; William Rea; Ning-Sheng Cai; David Aguinaga; Lesley A Howell; Felix Hausch; Antonio Cortés; Josefa Mallol; Vicent Casadó; Carme Lluís; Enric I Canela; Sergi Ferré; Peter J McCormick
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

9.  Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.

Authors:  Jordi Bonaventura; Gemma Navarro; Verònica Casadó-Anguera; Karima Azdad; William Rea; Estefanía Moreno; Marc Brugarolas; Josefa Mallol; Enric I Canela; Carme Lluís; Antoni Cortés; Nora D Volkow; Serge N Schiffmann; Sergi Ferré; Vicent Casadó
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

10.  A Significant Role of the Truncated Ghrelin Receptor GHS-R1b in Ghrelin-induced Signaling in Neurons.

Authors:  Gemma Navarro; David Aguinaga; Edgar Angelats; Mireia Medrano; Estefanía Moreno; Josefa Mallol; Antonio Cortés; Enric I Canela; Vicent Casadó; Peter J McCormick; Carme Lluís; Sergi Ferré
Journal:  J Biol Chem       Date:  2016-04-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.